Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kestra Medical TechnologiesKMTS -2.34%10 Net Current Asset Value is $3.82 as of Jan. 2026, which is 45% below its 10-year median of 6.98. GuruFocus rates KMTS with a GF Scoreâ„¢ of 10/100. The stock has 4 warning signs investors should review. Among 569 Medical Devices & Instruments companies, Kestra Medical Technologies ranks worse than 58.52% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Kestra Medical Technologies's net current asset value per share for the quarter that ended in Jan. 2026 was $3.82.
The historical rank and industry rank for Kestra Medical Technologies's Net Current Asset Value or its related term are showing as below:
KMTS'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.11 Med: 6.98 Max: 12.5
Current: 6.35
During the past 4 years, the highest Price-to-Net-Current-Asset-Value Ratio of Kestra Medical Technologies was 12.50. The lowest was 6.11. And the median was 6.98.
KMTS's Price-to-Net-Current-Asset-Value is ranked worse than 58.52% of 569
companies
in the Medical Devices & Instruments industry
Industry Median: 4.91
vs KMTS: 6.35
Kestra Medical Technologies (NAS:KMTS) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of GrahamÂ’s strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Kestra Medical Technologies Net Current Asset Value Related Terms
Kestra Medical Technologies Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kestra Medical Technologies Net Current Asset Value Chart
KMTS vs ATRC, STAA, BLFS: Net Current Asset Value Comparison
For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kestra Medical Technologies Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Kestra Medical Technologies's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $3.82 mean?
Kestra Medical Technologies (KMTS) has a Net Current Asset Value of $3.82 as of Jan. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Kestra Medical Technologies and its competitors. This is 45% below median its historical median of 6.98. Over the past decade, Kestra Medical Technologies' Net Current Asset Value has ranged from 6.11 to 12.50. According to the industry distribution chart, Kestra Medical Technologies ranks #333 out of 569 companies in the Medical Devices & Instruments industry, placing it in the top 58.5%.
Is Kestra Medical Technologies' Net Current Asset Value too high?
Kestra Medical Technologies' current Net Current Asset Value of $3.82 is 45% below median its 10-year median of 6.98. Over the past 10 years, this metric has ranged from a low of 6.11 to a high of 12.50. The Medical Devices & Instruments industry median Net Current Asset Value is 4.91. Kestra Medical Technologies' value of $3.82 is 22.2% below this industry median. Based on the distribution chart, Kestra Medical Technologies ranks #333 out of 569 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kestra Medical Technologies has a GF Scoreâ„¢ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' Net Current Asset Value compare to ATRC and STAA?
According to the Medical Devices & Instruments industry distribution chart, Kestra Medical Technologies ranks #333 out of 569 companies for Net Current Asset Value. This places Kestra Medical Technologies in the lower half of its industry. The industry median Net Current Asset Value is 4.91. Kestra Medical Technologies' value of $3.82 is 22.2% below this benchmark. Historically, Kestra Medical Technologies' own Net Current Asset Value has ranged from 6.11 to 12.50 over the past decade. While the company's 10-year median is 6.98 vs. the industry median of 4.91, Kestra Medical Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.91, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kestra Medical Technologies's current Net Current Asset Value of $3.82 is 22.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Kestra Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current Net Current Asset Value is $3.82, which is 45% below median its own 10-year median of 6.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current Net Current Asset Value of $3.82. The current Net Current Asset Value is $3.82, which is 45% below median its 10-year median of 6.98 and 22.2% below the Medical Devices & Instruments industry median of 4.91. Kestra Medical Technologies' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current Net Current Asset Value is $3.82 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
10GF Score
Get the complete analysis for KMTS
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMTS has been successfully added to your 
